Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC
Introduction: Combination chemoimmunotherapy including pemetrexed and a PD(L)1 inhibitor is a common first-line systemic therapy approach for patients with metastatic nonsquamous NSCLC. Patients often discontinue maintenance pemetrexed due to adverse effects, and little is known about the impact of...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2024-11-01
|
| Sarja: | JTO Clinical and Research Reports |
| Aiheet: | |
| Linkit: | http://www.sciencedirect.com/science/article/pii/S2666364324000870 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|